Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
famitinib + dalpiciclib + fulvestrant
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
famitinib + dalpiciclib + fulvestrant is a combination therapy being investigated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The regimen consists of dalpiciclib (SHR6390), a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); famitinib, a multi-targeted tyrosine kinase inhibitor that targets VEGFR2, PDGFR, and c-Kit; and fulvestrant, a selective estrogen receptor degrader (SERD). Dalpiciclib works by arresting the cell cycle in the G1 phase, while famitinib inhibits angiogenesis and tumor cell proliferation, and fulvestrant blocks estrogen-mediated signaling. This triplet combination is being evaluated in Phase 1b/2 clinical trials, such as those conducted at Henan Cancer Hospital, to improve outcomes in patients with heavily pretreated or advanced breast cancer.
- Brand names
- AiRuikangFaslodex
- Other names
- famitinib + dalpiciclib + fulvestrantSHR6390 + SHR1020 + fulvestrantdalpiciclib + famitinib + fulvestrant
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on famitinib + dalpiciclib + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on famitinib + dalpiciclib + fulvestrant.